Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 999 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment Gel Clear all
Completed Phase 3 Interventional

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

NCT05180708
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
QTORIN 3.9% rapamycin anhydrous gel, Vehicle
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Palo Alto, California • New Haven, Connecticut • Orange Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Phase 4 Interventional Results available

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

NCT02616250
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available

Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT02208297
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
Loteprednol Etabonate Gel (BID), Vehicle Gel (BID)
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens

NCT00495313
View directory record Official record
Conditions
Rosacea
Interventions
doxycycline
Drug
Lead sponsor
CollaGenex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
7
States / cities
Omaha, Nebraska • Las Vegas, Nevada • Arlington, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2008 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

NCT04992546
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PRN473 (SAR444727), Placebo
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Long Beach, California • Los Angeles, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 9, 2026, 3:47 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

NCT02796066
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Vehicle, TSN2898
Drug
Lead sponsor
Thesan Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
4
States / cities
San Diego, California • Miami, Florida • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 9, 2026, 3:47 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers

NCT00318214
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Diabetes Complications
Interventions
MRE0094, Vehicle gel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Not applicable Interventional Results available

Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients

NCT04256512
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Medical Device Usage and Evaluation, Questionnaire Administration
Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination Facial Aesthetic Treatment in Millennials

NCT04755595
View directory record Official record
Conditions
Dermatological Non-Disease
Interventions
Botox Cosmetic Injectable Product, Juvéderm Voluma XC, Juvéderm Volbella XC
Drug · Device
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
24 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Not applicable Interventional

The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain

NCT05542381
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Loteprednol Etabonate Ophthalmic Gel [Lotemax], Refresh Lubricant Eye Drops [Artificial Tears]
Drug · Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Phase 2 Interventional

CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea

NCT04886739
View directory record Official record
Conditions
Rosacea
Interventions
CGB-400, Vehicle Gel
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 9, 2026, 3:47 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels

NCT03920644
View directory record Official record
Conditions
Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness
Interventions
Scopolamine Transdermal Patch [Transderm Scop], Scopolamine, Placebo Patch, Placebo Gel
Drug
Lead sponsor
Naval Aeromedical Research Unit, Dayton
Federal
Eligibility
18 Years to 59 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

NCT02462187
View directory record Official record
Conditions
Genital Warts, Perianal Warts
Interventions
NVN1000 8% Gel, NVN1000 16%, Vehicle, NVN1000 24%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Fountain Valley, California • Lomita, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Phase 2 Interventional

A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203

NCT01386567
View directory record Official record
Conditions
Hypogonadism, Low Testosterone
Interventions
Androxal (enclomiphene citrate), Testim (topical testosterone)
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Garden Grove, California • Sacramento, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available

Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence

NCT00909181
View directory record Official record
Conditions
Urge Urinary Incontinence, Urinary Frequency
Interventions
Oxybutynin, Placebo
Drug
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
55
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Laguna Hills, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Phase 4 Interventional Results available

Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism

NCT03887936
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypogonadism
Interventions
Testosterone gel 1.62%, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 70 Years · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults

NCT02044081
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Rinse, Placebo, C16G2 Gel
Drug
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Kalispell, Montana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Efficacy and Tolerance of 2 Acne Treatment Regimens on Subjects With Mild to Moderate Acne

NCT03124381
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Cleanser, Acne Mask, Cleanser, Gel-Cream, Acne Mask
Device
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years to 40 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Albuquerque, New Mexico • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 9, 2026, 3:47 AM EDT
Completed No phase listed Observational

Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis

NCT05810194
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
StrataXRT, Calendula, Aquaphor
Device · Drug
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Efficacy of Experimental Gel to Foam Dentifrices in Dental Erosion

NCT01657903
View directory record Official record
Conditions
Dental Erosion, Acid Wear
Interventions
Sodium Fluoride, Potassium nitrate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 9, 2026, 3:47 AM EDT
Terminated Phase 3 Interventional

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

NCT01849965
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel, Standard of Care gel, Aquasite
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 9, 2026, 3:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Localized Therapeutics for the Treatment of Gastrointestinal Disorders

NCT02290665
View directory record Official record
Conditions
Healthy Adults
Interventions
Thermosensitive gel rectal formulation, Saline enema
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 9, 2026, 3:47 AM EDT
Not listed No phase listed Observational

Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

NCT03644771
View directory record Official record
Conditions
Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function
Interventions
Acthar
Drug
Lead sponsor
Greater Boston Medical Associates
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 9, 2026, 3:47 AM EDT